Cover

Loading…
More Information
Summary:Postupak za dobijanje anhidrovanog transdermalnog preparata, naznačen time, što se 5-15% mas. optički aktivnog ili racemskog N-metil-N-(fenil-2-propil)-2-propinilamina ili N-metil-N-(1-(4-fluoro-fenil)-2-propil)-2-propinilamina ili njihove podesne soli inkorporira u smešu koja se sastoji od 40-70 mas. % tečnog polioksietilenglikola, 10-20 mas. % čvrstog polioksietilenglikola, 2-30 mas. % nejonskog površinski aktivnog sredstva, 2-20 mas. % propilenglikola i po potrebi mogu se dodati druga pomoćna sredstva. The invention concerns an anhydrous transdermal preparation comprising in a 20-100% lyotropic liquid crystalline arrangement: 5-15 w.% of optically active or racemic N-methyl-N-(phenyl-2-propyl)-2-propynylamine or N-methyl-N-(1-(4-fluoro-phenyl)-2-propyl)-2-propynylamine or their therapeutically acceptable salts, 40-70 w.% of liquid polyoxyethyleneglycol, 10-20 w.% of solid polyoxyethyleneglycol, 2-30 w.% of a nonionic surface active agent, 2-20 w.% of propyleneglycol, if desired 0.5-2 w.% of a polymer the a value of which is > 0.6, and if desired other auxiliary agents.
Bibliography:Application Number: YU19920000384